Minimal Residual Disease Dynamics After Venetoclax–Obinutuzumab Treatment
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study
J. Clin. Oncol 2021 Dec 20;39(36)4049-4060, O Al-Sawaf, C Zhang, T Lu, MZ Liao, A Panchal, S Robrecht, T Ching, M Tandon, AM Fink, E Tausch, C Schneider, M Ritgen, S Böttcher, KA Kreuzer, B Chyla, D Miles, CM Wendtner, B Eichhorst, S Stilgenbauer, Y Jiang, M Hallek, K FischerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.